Clinical Trials /

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

NCT03801304

Description:

The majority of patients diagnosed with advanced NSCLC are treated with platinum-doublet chemotherapy regimens, except those harboring specific oncogenic drivers such as epidermal growth-factor-receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In the second-line setting, response rates remain low and median survival rarely exceeds 10 months. Over the past few years, several checkpoint inhibitors targeting programmed cell death protein-1 (PD1) or its ligand (PDL1) used as second-line therapies generated evidence of improving survival and, more recently, as first-line NSCLC treatment. Although pembrolizumab (anti-PD1) was recently approved as first-line treatment for patients with at least 50% of their NSCLC cells expressing PDL1, many patients are still not benefiting from this first-line agent. For patients with relapsed NSCLC, atezolizumab (anti-PDL1) prolonged survival compared to docetaxel in the phase II POPLAR and phase III OAK trials. Novel concepts of synergic action between immunotherapy and chemotherapy have emerged recently. However, those types of treatments are given for different durations: chemotherapy is allowed for only a short period (rarely exceeding 6 cycles), while anti-PDL1 can be continued for several months until loss of its clinical benefit. Metronomic chemotherapy is defined as low-dose and frequent chemotherapy administration, without prolonged drug-free breaks. Metronomic administration of oral vinorelbine has been tested against breast cancer and advanced refractory NSCLC. The combination could have immunostimulatory effects: induction of immunogenic cancer-cell death, enhancement of antigen presentation through dendritic cell modulation, increased cancer-cell immunogenicity, preferential depletion of regulatory T cells, modulation of myeloid-derived suppressor cells, enhancement of the cytotoxic activity of immune-effector cells.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer
  • Official Title: Open Label Phase II Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

Clinical Trial IDs

  • ORG STUDY ID: 29BRC18-0005 (VinMetAtezo)
  • NCT ID: NCT03801304

Conditions

  • Non-small Cell Lung Cancer

Interventions

DrugSynonymsArms
AtezolizumabAtezolizumab associated with vinorelbine
VinorelbineAtezolizumab associated with vinorelbine

Purpose

The majority of patients diagnosed with advanced NSCLC are treated with platinum-doublet chemotherapy regimens, except those harboring specific oncogenic drivers such as epidermal growth-factor-receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In the second-line setting, response rates remain low and median survival rarely exceeds 10 months. Over the past few years, several checkpoint inhibitors targeting programmed cell death protein-1 (PD1) or its ligand (PDL1) used as second-line therapies generated evidence of improving survival and, more recently, as first-line NSCLC treatment. Although pembrolizumab (anti-PD1) was recently approved as first-line treatment for patients with at least 50% of their NSCLC cells expressing PDL1, many patients are still not benefiting from this first-line agent. For patients with relapsed NSCLC, atezolizumab (anti-PDL1) prolonged survival compared to docetaxel in the phase II POPLAR and phase III OAK trials. Novel concepts of synergic action between immunotherapy and chemotherapy have emerged recently. However, those types of treatments are given for different durations: chemotherapy is allowed for only a short period (rarely exceeding 6 cycles), while anti-PDL1 can be continued for several months until loss of its clinical benefit. Metronomic chemotherapy is defined as low-dose and frequent chemotherapy administration, without prolonged drug-free breaks. Metronomic administration of oral vinorelbine has been tested against breast cancer and advanced refractory NSCLC. The combination could have immunostimulatory effects: induction of immunogenic cancer-cell death, enhancement of antigen presentation through dendritic cell modulation, increased cancer-cell immunogenicity, preferential depletion of regulatory T cells, modulation of myeloid-derived suppressor cells, enhancement of the cytotoxic activity of immune-effector cells.

Trial Arms

NameTypeDescriptionInterventions
Atezolizumab associated with vinorelbineExperimentalAtezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle. Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg.
  • Atezolizumab
  • Vinorelbine

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed NSCLC;

          -  Locally advanced and/or metastatic stage IV NSCLC (according to American Joint
             Committee on Cancers) or recurrent NSCLC);

          -  Patients without activating EGFR mutation or ALK rearrangement and ROS1 fusions.

          -  Subject has provided a formalin-fixed tumor-tissue sample of a tumor-lesion biopsy,
             either at the time of or after metastatic disease was diagnosed AND from a site not
             previously irradiated to assess for PDL1 status. Archived tissue may be acceptable;

          -  Patients must have a measurable lesion (RECIST V1.1);

          -  Progressive disease after first-line platinum-doublet-based chemotherapy according to
             RECIST V.1.1;

          -  Age ≥18 years, either sex;

          -  Eastern Collaborative Oncology Group Performance status (ECOG PS) 0, 1 or 2;

          -  Life expectancy exceeds 12 weeks;

          -  No history of other malignancy within the last 5 years, except for adequately treated
             carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin;

          -  Adequate organ function, demonstrated by the following laboratory results within 3
             weeks prior to randomization: Normal hepatic function: bilirubin <1.5 × normal (N),
             Alanine aminotransferase and Aspartate aminotransferase <2.5 × N or <5 × N if liver
             metastasis is present;

          -  Normal renal function (calculated creatinine clearance ≥45 mL/min);

          -  Normal calcemia;

          -  Normal hematological function (polynuclear neutrophils >1.5 G/L, platelets >100 G/L);

          -  Women of child-bearing potential must use effective contraception;

          -  Men might be surgically sterile or accept to use an effective contraceptive procedure
             during and until 6 months after the treatment;

          -  Written informed consent to participate in the study

          -  Patient with social insurance

        Exclusion Criteria:

          -  ECOG PS >2;

          -  Known hypersensitivity to immunotherapy;

          -  Small-cell lung cancer, bronchioloalveolar cancer, neuroendocrine cancer;

          -  Tumor harbors EGFR-sensitizing (activating) mutations or ALK translocations or ROS1
             fusions and that justify treatment with targeted therapy ;

          -  Chemotherapy, hormonotherapy, immunotherapy or tyrosine-kinase inhibitors within the
             past 4 weeks prior to treatment with the trial drug;

          -  Radiotherapy (except bone or brain) within the past 3 months prior to baseline
             imaging;

          -  Medical contraindication to oral vinorelbine;

          -  Persistence of clinical adverse events related to prior treatment;

          -  Active brain metastases (e.g. stable for <4 weeks, no adequate previous radiotherapy,
             symptomatic, requiring anticonvulsants; dexamethasone will be allowed if administered
             at a stable dose <10 mg/day for at least 1 month before randomization);

          -  Concurrent radiotherapy, except for palliative bone irradiation.

          -  Other concurrent severe illnesses (congestive heart failure, unstable angina,
             significant arrhythmia or myocardial infarction <12 months before study entry);

          -  Active or prior documented autoimmune or inflammatory disorders;

          -  Active B hepatitis, HIV infection …;

          -  Psychiatric or neurological disorders preventing the patient from understanding the
             nature of the trial;

          -  Grade-3 peripheral neuropathy;

          -  Uncontrolled infection;

          -  Interstitial lung disease or pneumonitis requiring steroid management;

          -  Corticosteroid therapy exceeding 10 mg/day;

          -  Other severe organic disorders not allowing inclusion in the trial;

          -  Malabsorption syndrome;

          -  Pregnancy or breast-feeding;

          -  Follow-up not possible; and incarcerated or institutionalized patients.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Occurrence of death or progression of the disease
Time Frame:4 months
Safety Issue:
Description:To evaluate the occurrence of death or progression of the disease

Secondary Outcome Measures

Measure:Emergence of adverse events (Safety and tolerability)
Time Frame:12 months
Safety Issue:
Description:To evaluate the safety outcomes, tolerability, adverse events frequency
Measure:Occurrence of death
Time Frame:12 months
Safety Issue:
Description:To evaluate the occurrence of death over 12 months of follow-up
Measure:Objective Response Rate
Time Frame:4 months
Safety Issue:
Description:To evaluate the objective Response Rate and Disease Control Rate
Measure:Following of the quality of life
Time Frame:12 months
Safety Issue:
Description:The scale EuroQol 5 dimensions (EDQ5) is used to evaluate the quality of life. The EQ-5D scale is a standardised measure of health status to provide a simple, generic measure of health for clinical and economic appraisal, whih is divided by the EQ-5D descriptive system (mobility, self care, usual activities, pain/discomfort, anxiety/depression) and the EQ Visual Analogue scale (EQ VAS). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems).
Measure:Following of the quality of life
Time Frame:12 months
Safety Issue:
Description:The EORTC QLQ-C30 is a questionnaire with 30 questions developed to assess the quality of life of cancer patients. An essential aspect of the "modular" approach to QOL assessment adopted by the EORTC Quality of Life Group is the development of modules specific to tumour site, treatment modality, or a QOL dimension, to be administered in addition to the core questionnaire (EORTC QLQ-C30).

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:University Hospital, Brest

Last Updated